Angiex Doses First Patient in Groundbreaking AGX101 Clinical Trial
Angiex has reached a major milestone by dosing the first patient in its Phase 1 clinical trial for AGX101, a novel Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) designed to treat solid tumors. AGX101 targets TM4SF1, a protein expressed in both tumor cells and blood vessels that support cancer growth. By delivering chemotherapeutic payloads directly into the nucleus of cancer cells and attacking the tumor’s blood supply, AGX101 aims to disrupt tumor proliferation and invasion.
The Phase 1 trial is an open-label, dose-escalation and expansion study, assessing safety, pharmacokinetics, and preliminary anti-tumor activity. Preclinical studies have shown AGX101's unique mechanism of action and its ability to selectively target and kill both tumor cells and endothelial cells. This approach offers hope for cancers that are resistant to existing therapies, with no known mechanisms of resistance to AGX101.
Angiex partnered with Abzena, a contract development and manufacturing organization (CDMO), to produce the clinical trial material. Abzena’s integrated services, including bioconjugation and cGMP manufacturing, have been instrumental in advancing AGX101 into the clinic. Matt Stober, CEO of Abzena, emphasized the importance of the collaboration in rapidly progressing AGX101 into human trials.
With its innovative approach, AGX101 has the potential to reshape cancer treatment by addressing a fundamental vulnerability—its dependence on blood supply. This trial represents an exciting step forward for patients facing aggressive, hard-to-treat cancers.
ADC Review’s coverage of AGX101 is significant because it highlights Angiex’s innovative work within the highly specialized antibody-drug conjugate space. As a leading publication for developments in ADCs, ADC Review emphasizes the scientific importance of Angiex’s progress and its potential impact on future oncology treatments.